Pancreatic cancer is difficult to resect due to its unique challenges, often leading to
incomplete tumor resections. Fluorescence-guided surgery (FGS), also known as …

Patients with unresectable pancreatic ductal adenocarcinoma (UR-PDAC) are traditionally
treated with palliative chemotherapy. The aim of this study was to evaluate the safety and …

Pancreatic ductal adenocarcinoma (PDAC) patients eligible for curative surgery undergo
unpredictable disease relapse. Even patients with a good pathological response after …

In the end of the twentieth century, the world entered the era of high-tech and personalized
medicine, characterized by the introduction of targeted drugs into clinical practice. Selective …

Background The pathologic assessments of tumor response after neoadjuvant
chemoradiotherapy (NACRT) are critical to improving the prognostic stratification for patients …

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant lethal disease due to its
asymptomatic at its early lesion of the disease and drug resistance. Target therapy …

The diagnosis and monitoring of disease through the detection of circulating protein
biomarkers is a growing field in the practice of oncology. The search for more effective …

В конце ХХ века мир вступил в эру высокотехнологичной и персонализированной
медицины, которая характеризуется внедрением в клиническую практику таргетных …

Mucins are a family of glycoproteins that have recently been the focus of intense
investigation for fluorescence-guided surgery of cancer due to their overexpression in many …

В конце ХХ века мир вступил в эру высокотехнологичной и персонализированной
медицины, которая характеризуется внедрением в клиническую практику таргетных …